Total Funding
68
57
Total FundingPost-IPO Equity raised
Growth Score
-10 pts
Heat Score
-1 pts
Company Performance Metrics
Score
Trend
AI Content may contain mistakes and is not legal, financial or investment advice.Learn more.
Growth Score - The measure of growth based on company activity, operational metrics, and investments
Growth Trend - The change in the growth score over the given time period
Heat Score - The measure of the market interest, media activity, and Crunchbase profile activity
Heat Trend - The change in the heat score over the given time period
Recent Events
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
See more interactive data and historical milestones on desktop for the best experience
11843
Alpha Cognition specializes in developing treatments for underserved neurodegenerative diseases.
- Jayant Panchal: CEO & Co-FounderPast Role: Goodybag, CEO & Co-Founder
Denis Kay: Co-Founder & Chief Scientific Officer
About the Company
Alpha Cognition is a clinical-stage, biopharmaceutical company developing treatments for under-served neurodegenerative diseases. It features ALPHA-1062, a patented new chemical entity that has demonstrated safety and improved tolerability in human clinical trials. It is being developed as a new acetylcholine esterase inhibitor for the treatment of
dementia of Alzheimer’s type, with minimal gastrointestinal side effects and novel routes of administration.
